DAE HWA PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10,210 KRW | +1.39% |
|
-5.20% | +8.85% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2018 | 110B 81.06M | Sales 2019 | 115B 84.35M | Capitalization | 223B 164M |
|---|---|---|---|---|---|
| Net income 2018 | 6.65B 4.89M | Net income 2019 | 10.54B 7.76M | EV / Sales 2018 | 3.44 x |
| Net Debt 2018 | 28.81B 21.2M | Net Debt 2019 | 39.64B 29.18M | EV / Sales 2019 | 2.29 x |
| P/E ratio 2018 |
52.7
x | P/E ratio 2019 |
21.3
x | Employees | 308 |
| Yield 2018 |
0.76% | Yield 2019 |
1.17% | Free-Float | 64.95% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.39% | ||
| 1 week | -5.20% | ||
| Current month | -7.77% | ||
| 1 month | +3.76% | ||
| 3 months | +10.74% | ||
| 6 months | -1.92% | ||
| Current year | +8.85% |
1 week
10 010.00
10 920.00
1 month
9 280.0012 360.00
Current year
8 680.0013 670.00
1 year
7 390.0015 980.00
3 years
5 940.0015 980.00
5 years
5 820.0023 000.00
10 years
5 820.0059 700.00
| Managers | Title | Age | Since |
|---|---|---|---|
Byung-Tae Noh
CEO | Chief Executive Officer | 62 | 85-12-14 |
Eun-Seok Kim
CEO | Chief Executive Officer | 48 | 08-01-31 |
Jae-Seong Na
DFI | Director of Finance/CFO | 55 | 93-01-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Eun-Seok Kim
CEO | Chief Executive Officer | 48 | 08-01-31 |
Byung-Tae Noh
CEO | Chief Executive Officer | 62 | 85-12-14 |
Sang-Tae Lee
BRD | Director/Board Member | 59 | 89-02-28 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-14 | 10,210 | +1.39% | 52,915 |
| 24-05-13 | 10,070 | -0.79% | 50,632 |
| 24-05-10 | 10,150 | -3.88% | 143,591 |
| 24-05-09 | 10,560 | -3.03% | 102,001 |
| 24-05-08 | 10,890 | +1.11% | 67,086 |
End-of-day quote Korea S.E., May 13, 2024
More quotes
DAE HWA PHARM CO.,LTD. is a Korea-based company engaged in the manufacture of pharmaceuticals. The Companyâs products include skeletal muscle relaxants, gastro-intestinal drugs, corticosteroids, antihistamines, cardiovascular drugs, drugs for liver diseases, vitamins, tonics, antibiotics, injections, topical drugs, anti-inflammatory enzymes, analgesics, antipyretics, plaster, cough suppressants, expectorants and mucolytics, drugs for hemorrhoid disease and other prescription drugs, as well as over-the-counter (OTC) drugs. The Company distributes its products within domestic market and to overseas markets. On August 22, 2013, it acquired a certain shares of a Korea-based company, which is mainly engaged in the manufacture of medicine raw materials and development of medical devices. After the transaction, the Company held a 100% stake of the Korea-based company.
Sector
Pharmaceuticals
Calendar
2024-08-08
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +8.85% | 131M | |
| +14.92% | 74.45B | |
| +11.35% | 9.18B | |
| +60.16% | 5.03B | |
| -12.85% | 5.02B | |
| +1.60% | 3.82B | |
| -19.20% | 2.41B | |
| +18.40% | 2.39B | |
| -29.25% | 2.27B | |
| +24.62% | 2.26B |
- Stock Market
- Equities
- A067080 Stock
